Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

MTX652

Source date not recordedAnalyse record ↗

Investigational selective USP30 inhibitor designed to improve mitochondrial quality by enhancing mitophagy, initially developed for acute kidney injury.

Modality
peripherally acting small-molecule USP30 inhibitor
Availability (US)
Phase 2-ready after completed Phase 1; divested to Dimerix in July 2026
Biomarkers
USP30 inhibition; mitophagy target engagement; pharmacokinetics; kidney-injury measures
Hallmark targeted
mitochondrial dysfunction, mitophagy, proteostasis
Kind
investigational drug
Clinical trials
Completed first-in-human Phase 1 study; FDA-cleared Phase 2 program in acute kidney injury